Evercore ISI analyst Daniel Markowitz initiated coverage of Inspire Medical (INSP) with an Outperform rating and $150 price target The neurostimulation company focused on the greater than $10B obstructive sleep apnea market is down 30% since Q2 on the back of a fiscal year guide down as investors debate whether issues are purely transitional related to the next gen launch of Inspire V or structural, the analyst tells investors. However, the firm believes the headwinds are temporary and Inspire is positioned for a “strong recovery” in 2026 and beyond.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Systems: Hold Rating Amid Leadership Transition and Stable FY25 Guidance
- Inspire Medical Systems CFO to Step Down
- Inspire Medical announces departure of CFO Rick Buchholz
- Inspire Medical reaffirms FY25 EPS view 40c-50c, consensus 86c
- Inspire Medical backs FY25 EPS view 40c-50c, consensus 86c